Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Outline
3. Family history as a risk factor for early CHD
4. Criteria for useful CHD-related DNA tests (1)
5. Analytical validity- accuracy and individual variation
6. Clinical validity- how accurate is the risk estimate?
7. Risk estimated for genetic effects
8. Clinical utility- how do risk score algorithms work?
9. Risk score methods- PROCAM/Framingham
10. CRFs predict poorly in UK middle-aged men
11. CRP: origin, clearance and function
12. Adding CRP to algorithm risk score in NPHSII
13. Can genotype predict risk over trait measure?
14. Major new "gene" for MI/CHD
15. Experts believe in the new method
16. CDNK2A genotype and prospective CHD risk (1)
17. CDNK2A genotype and prospective CHD risk (2)
18. CDNK2A genotype and prospective CHD risk (3)
19. Six new GWAS SNPs for risk prediction
20. Genotypes of modest risk in combination
21. Risk genotype- frequency and odds ratios
22. Genetic tests for CHD: lipid gene SNPs
23. DNA information to optimise risk stratification
24. Measures of predictive performance
25. Use genetic information to stratify intermediate risk
26. Model clinical utility of adding CDKN2A
27. Risk score distribution - CRFs only
28. Risk score distribution - CRFs and genotype
29. Criteria for useful CHD-risk DNA tests (2)
30. ELSI - risk perception and behaviour change (1)
31. ELSI - risk perception and behaviour change (2)
32. Perception of risk information
33. Smoking cessation motivation by DNA risk: design
34. Smoking cessation motivation by DNA risk: results
35. DNA tests & CHD risk stratification: are we ready?
36. Genetic testing for CHD risk: fact!

Topics Covered

• Family history is a strong independent risk factor for early CHD
• Criteria for useful CHD-Risk DNA tests
• Analytical validity
• Clinical validity
• Risk estimates for genetic effects
• Clinical utility
• Risk score methods
• CRP: origin, clearance and function
• Is it likely that genotype will predict risk over and above trait measure?
• CDNK2A genotype and prospective CHD risk in NPHSII
• Six GWAS SNPs for risk prediction
• Will genotypes of modest risk be useful in combination
• Risk genotype frequency distribution and associated odds ratios
• Genetic tests for CHD: using lipid gene SNPs
• Can we use DNA information to optimize risk stratification
• Measures of predictive performance
• Use genetic information to stratify intermediate risk
• Model clinical utility of adding CDKN2A risk information
• Risk score distribution
• CRFs and genotype
• ELSI: risk perception and behaviour change
• Ethical, legal and social impact
• Perception of risk information
• Smoking cessation motivation by DNA risk: design and results
• DNA tests and CHD risk stratification: are we ready now?

Links

Series:

• Genetics of Cardiovascular Disease

Categories:

• Clinical Practice
• Genetics & Epigenetics

Therapeutic Areas:

• Cardiovascular & Metabolic

Talk Citation

Humphries, S. (2008, November 24). Genetic testing for CHD risk: fact or fiction? [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 19, 2024, from https://hstalks.com/bs/1061/.
Export Citation (RIS)

Publication History

• Published on November 24, 2008
• Archived on February 25, 2021

Financial Disclosures

• Professor Humphries is the Medical Director of StoreGene a UCL spin out company that offers DNA testing for Cardiovascular Disease risk including testing for FH. Professor Humphries is a consultant for Verve Therapeutics, a US based company that is developing gene-editing agents to treat individuals with hypercholesterolaemia, including those with FH.